Clinical Trial Update: All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating all-trans retinoic acid with a KPD regimen for relapsed or refractory multiple myeloma. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• All-trans Retinoic Acid (all-trans retinoic acid)
• KPD regimen

Snippet

Sponsor: The First Affiliated Hospital of Xiamen University | Conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Phase 2 | Status: RECRUITING